Autoimmune diseases are associated with a dramatically increased risk of atherosclerotic
cardiovascular disease and its clinical manifestations. The increased risk is consistent with …

Systemic lupus erythematosus (SLE) carries a significant risk of cardiovascular disease
(CVD). The prevalence of premature CVD is especially noteworthy because it occurs in …

Increased risk of premature cardiovascular disease (CVD) is well recognized in systemic
lupus erythematosus (SLE). Aberrant type I-Interferon (IFN)-neutrophil interactions contribute …

Objective Neutrophil dysregulation and the type I interferon (IFN) axis have been proposed
to contribute to premature cardiovascular disease, a leading cause of mortality in patients …

GlycA is a biomarker of systemic inflammation, quantifying both the protein concentrations
and glycosylation states of several acute phase proteins. GlycA has been shown to be …

Vascular disease is a major cause of morbidity and mortality in patients with systemic
autoimmune diseases, particularly systemic lupus erythematosus (SLE). Although comorbid …

Epidemiological and clinical studies have demonstrated a consistent relationship between
increased systemic inflammation and increased risk of cardiovascular events. In chronic …

Fundamental new insights regarding the role of mitochondrial dysfunction in innate immune
dysregulation in SLE pathogenesis have recently emerged. Defects in specific molecular …

Objectives Premature cardiovascular events in systemic lupus erythematosus (SLE)
contribute to morbidity and mortality, with no effective preventive strategies described to …

Objective Systemic lupus erythematosus (SLE) is an autoimmune disease with inflammation
as a critical feature. Recently, high‐density lipoprotein cholesterol (HDLc) have been …